| 40465-7 |
Glimepiride |
MCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glimepride [Mass/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
ng/mL |
|
|
|
|
|
|
DRUG/TOX |
|
40465-7 |
|
|
|
|
Both |
|
|
|
0 |
Glimepiride SerPl-mCnc |
|
|
|
N |
|
Amaryl; DRUG/TOXICOLOGY; Drugs; Glista OD; Level; Mass concentration; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR |
2.73 |
2.15 |
|
|
|
|
|
|
|
ng/mL |
|
|
|
0 |
| 40466-5 |
Herpes simplex virus 1 Ab.IgM |
PrThr |
Ser |
Pt |
Ord |
IF |
|
ACTIVE |
Herpes simplex virus 1 IgM Ab [Presence] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
Negative |
|
|
|
|
|
MICRO |
|
40466-5 |
|
IF |
|
|
Both |
|
|
|
0 |
HSV1 IgM Ser Ql IF |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Autoantibodies; Autoantibody; FA; Fluorescent antibody; Fluoresent; Herp splx; Herpes simplex virus 1 Ab; Herpes simplex virus 1 antibody; Herpes simplex virus 1 IgM; Herpes simplex virus type 1; Herpes simplex virus type I; HSV; HSV1; i; ID; IFA; Immune fluorescence; Immune globulin M; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin M; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SR; Time Resolved Fluorescence; TRF |
2.73 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40467-3 |
U1 small nuclear ribonucleoprotein Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
IB |
|
ACTIVE |
U1 small nuclear ribonucleoprotein IgG Ab [Units/volume] in Serum by Immunoblot |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
SERO |
|
40467-3 |
|
IB |
|
|
Both |
|
|
|
0 |
U1 snRNP IgG Ser IB-aCnc |
|
|
|
N |
|
ABS; Aby; ANA IgG; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Blt; Immune blot; Immune globulin G; Immunobl; Immunoblot; Immunoglobulin G; Nuc; Point in time; QNT; Quan; Quant; Quantitative; Random; RIBA; Ribonuclear protein; RNP; Serology; Serum; snRNP; SR; U1 RNP; U1 snRNP; U1RNP; WB; WBLOT; West blot; West blt; Western blot |
2.69 |
2.15 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
| 40468-1 |
SLC26A4 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
SLC26A4 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
PENDRIN GENE MUTATION ANALYSIS: GENOMIC DNA WAS EXTRACTED FROM BLOOD AND AMPLIFIED USING THE POLYMERASE CHAIN REACTION ( PCR )WITH PRIMERS TESTING EXONS 6,9,10, AND 19 OF THE PENDRIN ( PDS ) GENE. THE PCR PRODUCTS WERE SEQUENCED USING AN ABI FLUORESCENCE AUTOMATIC DNA SEQUENCER FOR DETECTION OF THE MOST COMMON PATHOGENIC MUTATIONS NOTED BELOW: L236P, K369E, A372V, E384G, T416P,2111INSGCTGG, T721M, H723R. RESULTS: NO EVIDENCE FOR THESE MUTATIONS. IMPRESSION: NO EVIDENCE BY DNA TESTING FOR THESE PATHOGENIC MUTATIONS IN THE TESTED EXONS OF THE PENDRIN PDS ) GENE. THIS TEST DOES NOT EXPLORE THE POSSIBILITY OF A MUTATION IN THE REMAINING EXONS, INTRONS OR THE PROMOTER REGION, AND DOES NOT EXAMINE FOR MUTATIONS IN OTHER GENES THAT CAN RESULT IN PEDRED SYNDROME. NOTE: DIRECT DNA SEQUENCING AS AN APPROACH TO MUTATION DETECTION HAS AN ESTIMATED 95% ACCURACY.IT IS NOT FEASIBLE TO INCLUDE CONTROLS FOR ALL POSSIBLE MUTATIONS. THEREFORE, SOME PATHOGENIC MUTATIONS MIGHT BE MISSED. |
|
|
|
|
|
MOLPATH.MUT |
|
40468-1 |
|
Molgen |
|
|
Both |
|
|
|
0 |
SLC26A4 gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; Deafness, autosomal recessive 4; DFNB4; Document; EVA; Finding; Findings; Genetics; Heredity; Heritable; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; NSRD4; PCR; PDS; Pendred syndrome; Pendrin (Sodium-independent chloride/iodide transporter); Point in time; Random; solute carrier family 26 (anion exchanger), member 4; Solute carrier family 26, member 4; TDH2B; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.15 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 40469-9 |
Hydroflumethiazide |
PrThr |
Urine |
Pt |
Ord |
|
|
ACTIVE |
Hydroflumethiazide [Presence] in Urine |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
40469-9 |
|
|
|
|
Both |
|
|
|
0 |
Hydroflumethiazide Ur Ql |
|
|
|
N |
|
Diucardin; DRUG/TOXICOLOGY; Drugs; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; UA; UR; Urn |
2.73 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 4047-7 |
Theophylline |
MCnc |
Bld |
Pt |
Qn |
|
|
ACTIVE |
Theophylline [Mass/volume] in Blood |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
4047-7 |
|
|
|
|
Both |
|
|
|
0 |
Theophylline Bld-mCnc |
|
|
|
Y |
|
Aminophylline; Biophyllin; Blood; Continus; DRUG/TOXICOLOGY; Drugs; Lasma; Level; Mass concentration; Nuelin; Phyllocontin; Point in time; Pro-vent; QNT; Quan; Quant; Quantitative; Random; Sabidal SR; Slo-Phyllin; Somophyllin; Somophylline; Theo; Theo-dur; Theolair; Uniphyllin; WB; Whole blood |
2.4 |
1 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 40470-7 |
Lymphocytes |
Naric |
Semen |
Pt |
Qn |
Microscopy.light.HPF |
|
ACTIVE |
Lymphocytes [#/area] in Semen by Microscopy high power field |
|
MIN |
DefinitionDescription |
|
|
/HPF |
|
|
|
|
|
|
HEM/BC |
|
40470-7 |
|
Microscopy.light.HPF |
|
|
Observation |
|
|
|
0 |
Lymphocytes #/area Smn HPF |
|
|
|
N |
|
#/area; Ejaculate; Genitourinary; GU; HEMATOLOGY/CELL COUNTS; LM; Lymp; Lymph; Lympho; Lymphocyte; Lymphs; Lymphs%; Micro; Micros; Microscopic; Number areic; Point in time; QNT; Quan; Quant; Quantitative; Random; Sem; Seminal fluid; Smn; SMPLS; URO; Urology |
2.7 |
2.15 |
|
|
|
|
|
|
|
/[HPF] |
|
|
|
0 |
| 40471-5 |
FBN1 gene targeted mutation analysis |
Prid |
Bld/Tiss |
Pt |
Nom |
Molgen |
|
ACTIVE |
FBN1 gene mutations found [Identifier] in Blood or Tissue by Molecular genetics method Nominal |
|
MIN |
DefinitionDescription |
|
|
|
Our final results indicate that the FBN1 gnen did not contain any detectable mutation that could be a cause of this patient's condition. However, the technology does not detect all possible mutaions in this gene that contains >240000 base pairs. |
|
|
|
|
|
MOLPATH.MUT |
|
40471-5 |
|
Molgen |
|
|
Both |
|
|
|
0 |
FBN1 gene Mut Anl Bld/T |
|
|
|
N |
|
ACMICD; Blood; ECTOL1; FBN; fibrillin 1; Fibrillin 1 (Marfan syndrome); Genetics; GPHYSD2; Heredity; Heritable; Identity or presence; Inherited; MASS; MFS1; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; Nominal; OCTD; PCR; Point in time; Random; SGS; SSKS; Tissue; Tissue, unspecified; WB; Weill-Marchesani syndrome; Whole blood; Whole blood or Tissue; WMS; WMS2 |
2.73 |
2.15 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section. |
0 |
| 40472-3 |
Tetradecadienoate/Creatinine |
MRto |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Tetradecadienoate (C14:2)/Creatinine [Mass Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
ug/mg creatinine |
|
|
|
|
|
|
CHEM |
|
40472-3 |
|
|
|
|
Observation |
|
|
|
0 |
Tdecadienoate/Creat Ur |
|
|
|
N |
|
C14:2; Chemistry; CR; Crea; Creat; Mass concentration ratio; Mass ratio; MCRto; Point in time; QNT; Quan; Quant; Quantitative; Random; Tdecadienoate; Tetradecadienoic acid; UA; UCr; UR; Urn |
2.7 |
2.15 |
|
|
|
|
|
|
|
ug/mg{creat} |
|
|
|
0 |
| 40473-1 |
Thermoactinomyces vulgaris 1 Ab |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Thermoactinomyces vulgaris 1 Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
40473-1 |
|
|
|
|
Both |
|
|
|
0 |
T vulgaris1 Ab Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Farmers lung; i; ID; Infectious Disease; InfectiousDisease; Lung; m23; m51; Microbiology; Ordinal; Point in time; PR; Pulmonary; Pulmonology; Ql; Qual; Qualitative; Random; Respiratory; Rm213; Screen; Serum; SR; T vulgaris; T vulgaris1; Thermoactnom |
2.73 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40474-9 |
Volatiles |
Prid |
XXX |
Pt |
Nom |
|
|
ACTIVE |
Volatiles and gases [Identifier] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
40474-9 |
|
|
|
|
Both |
|
|
|
0 |
Volatiles Spec |
|
|
|
N |
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Identity or presence; Illicit; Misc; Miscellaneous; Nominal; Other; Point in time; PotentialForAbuse; Random; Spec; To be specified in another part of the message; Unspecified; Volatile |
2.69 |
2.15 |
|
|
|
|
|
|
|
|
|
|
|
0 |
| 40475-6 |
WFS1 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
WFS1 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
MUTATION ANALYSIS OF THE WFS1 GENE IN FELIX MORAN WITH WOLFRAM SYNDROME WAS DONE BY SEQUENCE ANALYSIS OF ALL CODING EXONS AND INTRON/EXON BOUNDARIES OF THE WFS1 GENE (EXON 2-8). RESULTS: THIS PATIENT HARBOURS A HOMOZYGOUS 1230-1233DELCTCT MUTATION IN EXON 8 OF THE WFS1 GENE. CONCLUSION: THIS PATIENT HARBOURS AN APPARENTLY HOMOZYGOUS 1230-1233DELCTCT MUTATION IN THE WFS1 GENE. THIS MUTATION CAUSES A FRAMESHIFT AND INTRODUCES A PREMATURE STOPCODON AFTER 439 AMINO ACIDS, LEADING TO THE FORMATION OF A (PROBABLY NON FUNCTIONAL) TRUNCATED WFS1 PROTEIN. THE IDENTIFICATION OF THIS MUTATION IN APPARENTLY HOMOZYGOUS STATE CONFIRMS THE CLINICAL DIAGNOSIS OF WOLFRAM SYNDROME. CARRIER TESTING IS RECOMMENDED FOR RELATIVES. |
|
|
|
|
|
MOLPATH.MUT |
|
40475-6 |
|
Molgen |
|
|
Both |
|
|
|
0 |
WFS1 gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; CTRCT41; DFNA14; DFNA38; DFNA6; DIDMOAD; Document; Finding; Findings; Genetics; Heredity; Heritable; HGNC:13668; HGNC:2787; HGNC:2811; Inherited; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PCR; Point in time; Random; Tissue; Tissue, unspecified; WB; WFRS; WFS; WFSL; Whole blood; Whole blood or Tissue; Wolfram syndrome 1 (wolframin) |
2.66 |
2.15 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 40476-4 |
PARK2 gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
PARK2 gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
NO DNA SEQUENCE VARIANTS HAVE BEEN DETECTED THIS INDIVIDUAL DOES NOT POSSES ANY DETECTABLE SEQUENCE VARIANTS IN THE PARKIN GENE. THEREFORE, THE INDIVIDUAL IS UNLIKELY TO BE AFFECTED WITH, OR PREDISPOSED TO DEVELOPING, AUTOSOMAL RECESSIVE PARKINSONISM DUE TO MUTATIONS IN THE PARKIN GENE. REFERENCE RANGE: NO SEQUENCE ALTERATION DETECTED, NO DUPLICATION/DELETION DETECTED |
|
|
|
|
|
MOLPATH.MUT |
|
40476-4 |
|
Molgen |
|
|
Both |
|
|
|
0 |
PARK2 gene Mut Anl Bld/T |
|
|
|
N |
|
AR-JP; Blood; Document; Finding; Findings; Genetics; Heredity; Heritable; Inherited; LPRS2; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; PARKIN; parkin RBR E3 ubiquitin protein ligase; Parkinson disease (autosomal recessive, juvenile) 2; PCR; PDJ; Point in time; PRKN; Random; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.68 |
2.15 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 40477-2 |
L1CAM gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
L1CAM gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MIN |
DefinitionDescription |
|
|
|
MUTATION ANALYSIS: ANALYSIS PROCEEDED ON THE SUBMITTED GENOMIC DNA SAMPLE. ALL 28 CODING EXONS AND INTRON/EXON BOUNDARIES OF THE L1CAM GENE WERE SCREENED BY BI-DIRECTIONAL SEQUENCE ANALYSIS. RESULT: NO SEQUENCE CHANGES IN THE CODING REGION OF THE L1CAM GENE WERE IDENTIFIED AS COMPARED TO THE Normal PUBLISHED SEQUENCE OF THE GENE. INTERPRETATION: NO MUTATION IN THE X-LINKED L1CAM GENE WAS IDENTIFIED IN THIS ANALYSIS. L1CAM MUTATIONS ARE PRESENT IN 15-25% OF MALES WHO HAVE HYDROCEPHALUS, A Negative FAMILYHISTORY, AND NO OTHER L1CAM-ASSOCIATED FINDINGS. NINETY-THREE PERCENT OF MALES WITH AQUEDUCTAL STENOSIS, A POSITVE FAMILY HISTORY WITH TWO OR MORE AFFECTED FAMILY MEMBERS, AND AT LEAST ONE OTHER FEATURE OF L1CAM DISEASE SHOW MUTATIONS IN THIS GENE (FINCKH, ET AL (2000) AM J MED GENET 92:40-46). |
|
|
|
|
|
MOLPATH.MUT |
|
40477-2 |
|
Molgen |
|
|
Both |
|
|
|
0 |
L1CAM gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; CAML1; CD171; CD171 gene; Document; Finding; Findings; Genetics; Heredity; Heritable; HGNC:7086; HSAS; HSAS1; Hydrocephalus, stenosis of aqueduct of Sylvius 1 (HSAS1); Inherited; L1 cell adhesion molecule; MASA; Mental retardation, aphasia, shuffling gait and adducted thumbs (MASA) syndrome; MIC5; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; Mut; Mut Anl; Mutations; N-CAML1; N-CAM-L1; NCAM-L1; Neural cell adhesion molecule L1 precursor; PCR; Point in time; Random; S10; SPG1; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.73 |
2.15 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 40478-0 |
MAPT gene targeted mutation analysis |
Find |
Bld/Tiss |
Pt |
Doc |
Molgen |
|
ACTIVE |
MAPT gene targeted mutation analysis in Blood or Tissue by Molecular genetics method |
|
MAJ |
DefinitionDescription |
|
|
|
RESULTS: MUTATION DETECTED: NONE SIGNIFICANCE: Normal INTERPRETATION: A CITED MUTATION HAS NOT BEEN IDENTIFIED IN THE EXON 10 REGION OF THE TAU GENE IN THIS INDIVIDUAL. THIS FINDING REDUCES THE POSSIBILITY OF DEMENTIA AS A RESULT OF A MUTATION IN THE TAU GENE BY CLOSE TO 50%. THIS RISK MAY BE FURTHER DEFINED BY SEQUENCING THE ENTIRE TAU GENE. FUTHERMORE, THE IMPLICATIONS OF GENETIC TESTING CAN BE COMPLICATED AND GENETIC COUNSELING CAN BE A VALUABLE AID IN UNDERSTANDING THE RESULTS. |
|
|
|
|
|
MOLPATH.MUT |
|
40478-0 |
|
Molgen |
|
|
Both |
|
|
|
0 |
MAPT gene Mut Anl Bld/T |
|
|
|
N |
|
Blood; DDPAC; Disinhibition-dementia-Parkinsonism-amyotrophy complex; Document; Finding; Findings; FLJ31424; FTDP-17; G protein beta1/gamma2 subunit-interacting factor 1; Genetics; Heredity; Heritable; Inherited; MAPTL; Microtubule-associated protein tau; Molecular genetics; Molecular pathology; MOLPATH; MOLPATH.MUTATIONS; MSTD; MTBT1; MTBT2; Mut; Mut Anl; Mutations; PCR; Point in time; PPND; PPP1R103; Random; TAU; TAU gene; Tissue; Tissue, unspecified; WB; Whole blood; Whole blood or Tissue |
2.66 |
2.15 |
|
|
|
|
|
|
|
|
|
|
Based on LOINC Committee review (June 2016), "targeted" was added to the Component to clarify that this test is looking for a specific set of mutations as described in the LOINC User Guide under the Molecular Genetics section.; Based on LOINC Committee review (June 2019), updated the Property from "Prid" to "Find" and Scale from "Nar" to "Doc" to align with the current LOINC model for naming collections of information reported in narrative and/or structured formats. |
0 |
| 40479-8 |
Virus |
Prid |
Body fld |
Pt |
Nom |
Culture |
|
ACTIVE |
Virus identified in Body fluid by Culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
40479-8 |
|
Culture |
|
|
Both |
|
|
|
0 |
Virus Fld Cult |
|
|
|
N |
|
B/F; BF; bod; Bodies; Body fluid; Body fluid, unsp; C&S; Cult; Cultures; Fl; Fld; FLU; Fluid; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random |
2.79 |
2.15 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 4048-5 |
Theophylline |
MCnc |
Saliva |
Pt |
Qn |
|
|
ACTIVE |
Theophylline [Mass/volume] in Saliva (oral fluid) |
|
MIN |
DefinitionDescription |
|
|
ug/mL |
|
|
|
|
|
|
DRUG/TOX |
|
4048-5 |
|
|
|
|
Both |
|
|
|
0 |
Theophylline Sal-mCnc |
|
|
|
Y |
|
Aminophylline; Biophyllin; Continus; DRUG/TOXICOLOGY; Drugs; Lasma; Level; Mass concentration; Nuelin; Oral fluid; Phyllocontin; Point in time; Pro-vent; QNT; Quan; Quant; Quantitative; Random; Sabidal SR; Sal; Slo-Phyllin; Somophyllin; Somophylline; Theo; Theo-dur; Theolair; Uniphyllin |
2.42 |
1 |
|
|
|
|
|
|
|
ug/mL |
|
|
|
0 |
| 40480-6 |
Virus |
Prid |
Genital |
Pt |
Nom |
Culture |
|
ACTIVE |
Virus identified in Genital specimen by Culture |
|
NAM |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
40480-6 |
|
Culture |
|
|
Both |
|
|
|
0 |
Virus Genital Cult |
|
|
|
N |
|
C&S; Cult; Cultures; Gen; Genital tract; ID; Identity or presence; Infectious Disease; InfectiousDisease; Microbiology; Nominal; Point in time; Random; Urogenit; Urogenital |
2.79 |
2.15 |
|
|
|
|
|
|
|
|
|
|
Release 2.79: COMPONENT: Triggered by the coll w SCT:The understanding is that the word "identified" refers to the property "PRID", its presence in the component is redundant to the property. Therefore it is better to remove "identified" from the component.; |
0 |
| 40481-4 |
Methylenedioxymethamphetamine |
PrThr |
XXX |
Pt |
Ord |
|
|
ACTIVE |
Methylenedioxymethamphetamine [Presence] in Specimen |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
40481-4 |
|
|
|
|
Both |
|
|
|
0 |
MDMA Spec Ql |
|
|
|
N |
|
Addiction; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Ecstasy; Illicit; MDMA; Misc; Miscellaneous; Ordinal; Other; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; Spec; To be specified in another part of the message; Unspecified |
2.73 |
2.15 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
| 40482-2 |
Crystals.unidentified |
Naric |
Urine sed |
Pt |
Qn |
Microscopy.light.LPF |
|
ACTIVE |
Unidentified crystals [#/area] in Urine sediment by Microscopy low power field |
|
MIN |
DefinitionDescription |
|
|
/LPF |
|
|
|
|
|
|
UA |
|
40482-2 |
|
Microscopy.light.LPF |
|
|
Observation |
|
|
|
0 |
Unident Crys #/area UrnS LPF |
|
|
|
N |
|
#/area; Crys; Cryst; Crystal; Kidney; LM; Micro; Micros; Microscopic; Nephrology; NOS AB; Number areic; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; UA; Unident Crys; UR; URINALYSIS; Urine sediment; Urn; UrnS |
2.7 |
2.15 |
|
|
|
|
|
|
|
/[LPF] |
|
|
|
0 |
| 40483-0 |
Phosphate crystals.amorphous |
Naric |
Urine sed |
Pt |
Qn |
Microscopy.light.LPF |
|
ACTIVE |
Phosphate crystals amorphous [#/area] in Urine sediment by Microscopy low power field |
|
MIN |
DefinitionDescription |
|
|
/LPF |
|
|
|
|
|
|
UA |
|
40483-0 |
|
Microscopy.light.LPF |
|
|
Observation |
|
|
|
0 |
Amorph Phos Cry #/area UrnS LPF |
|
|
|
N |
|
#/area; AM; Amorph; Amorph Cry; Amorph Phos Cry; Amorphic; Crys; Cryst; Crystal; i Phos; Inorganic phosphate; Kidney; LM; Micro; Micros; Microscopic; Nephrology; Number areic; Phos; Phosphate total; Phosphorous; Phosphorus; Phosphrous; Pi; PO4; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; UA; UR; URINALYSIS; Urine sediment; Urn; UrnS |
2.7 |
2.15 |
|
|
|
|
|
|
|
/[LPF] |
|
|
|
0 |
| 40484-8 |
Urate crystals.amorphous |
Naric |
Urine sed |
Pt |
Qn |
Microscopy.light.LPF |
|
ACTIVE |
Urate crystals amorphous [#/area] in Urine sediment by Microscopy low power field |
|
MIN |
DefinitionDescription |
|
|
/LPF |
|
|
|
|
|
|
UA |
|
40484-8 |
|
Microscopy.light.LPF |
|
|
Observation |
|
|
|
0 |
Amorph Urate Cry #/area UrnS LPF |
|
|
|
N |
|
#/area; AM; Amorph; Amorph Cry; Amorph Urate Cry; Amorphic; Crys; Cryst; Crystal; Kidney; LM; Micro; Micros; Microscopic; Nephrology; Number areic; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; UA; UR; Urates; Uric acid; URINALYSIS; Urine sediment; Urn; UrnS |
2.73 |
2.15 |
|
|
|
|
|
|
|
/[LPF] |
|
|
|
0 |
| 40485-5 |
Urate crystals |
Naric |
Urine sed |
Pt |
Qn |
Microscopy.light.LPF |
|
ACTIVE |
Urate crystals [#/area] in Urine sediment by Microscopy low power field |
|
MIN |
DefinitionDescription |
|
|
/LPF |
|
|
|
|
|
|
UA |
|
40485-5 |
|
Microscopy.light.LPF |
|
|
Observation |
|
|
|
0 |
Urate Cry #/area UrnS LPF |
|
|
|
N |
|
#/area; Crys; Cryst; Crystal; Kidney; LM; Micro; Micros; Microscopic; Nephrology; Number areic; Point in time; QNT; Quan; Quant; Quantitative; Random; Renal; UA; UR; Urates; Uric acid; URINALYSIS; Urine sediment; Urn; UrnS |
2.73 |
2.15 |
|
|
|
|
|
|
|
/[LPF] |
|
|
|
0 |
| 40486-3 |
Protein/Creatinine |
Ratio |
Urine |
24H |
Qn |
|
|
ACTIVE |
Protein/Creatinine [Ratio] in 24 hour Urine |
|
MIN |
DefinitionDescription |
|
|
g/mmol;gm/mmol_cre |
|
|
|
|
|
|
UA |
|
40486-3 |
|
|
|
|
Observation |
|
|
|
0 |
Prot/Creat 24h Ur-Rto |
|
|
|
N |
|
1 day; 24 hours; 24HR; CR; Crea; Creat; PR; Prot; QNT; Quan; Quant; Quantitative; Ratios; Rto; UA; UCr; UR; URINALYSIS; Urn |
2.73 |
2.15 |
|
|
|
|
|
|
|
umol/g{creat} |
|
|
|
0 |
| 40487-1 |
Urea/Creatinine |
Ratio |
Urine |
Pt |
Qn |
|
|
ACTIVE |
Urea/Creatinine [Ratio] in Urine |
|
MIN |
DefinitionDescription |
|
|
mmol/g creatinine |
|
|
|
|
|
|
CHEM |
|
40487-1 |
|
|
|
|
Both |
|
|
|
0 |
Urea/Creat Ur-Rto |
|
|
|
N |
|
Chemistry; CR; Crea; Creat; Point in time; QNT; Quan; Quant; Quantitative; Random; Ratios; Rto; UA; UCr; UR; Urn |
2.7 |
2.15 |
|
|
|
|
|
|
|
mmol/g{creat} |
|
|
|
0 |
